t cell activity in successful treatment of chronic urticaria with omalizumabt细胞活性与omalizumab成功治疗慢性荨麻疹.pdf

Sánchez-Machín et al. Clinical and Molecular Allergy 2011, 9:11 /content/9/1/11 CMA COMMENTARY Open Access T cell activity in successful treatment of chronic urticaria with omalizumab 1 1 2 2 1 Inmaculada Sánchez-Machín , Javier Iglesias-Souto , Andrés Franco , Yvelise Barrios , Ruperto Gonzalez and Víctor Matheu 1,3,4,5,6* Abstract Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, it has been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient was partially controlled with cyclosporine at doses of 100 mg/12 h. However, she was still developing hives daily. Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced a decrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy on the activity of peripheral blood CD4+ T cells from the patient, in order to determine the potential modification of anti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4+ cells by ATP release was clearly increased demonstrating an enlarged CD4 activity. Omalizumab may be useful in the treatment of severe chronic urticaria. ATP activity of peripheral blood CD4+ T cells might be a non-subjective method to assess Omalizumab activity. We have read the interesting manuscript recently pub-